Back to search results

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Anatomic Stage III Breast Cancer AJCC v8 · Anatomic Stage IV Breast Cancer AJCC v8 · Locally Advanced Unresectable HER2-Negative Breast Carcinoma · Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma · Metastatic HER2-Negative Breast Carcinoma · Metastatic Hormone Receptor-Positive Breast Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Siteman Cancer Center at Washington University, St Louis, Missouri, United States

    Contact: Study coordinator (Farrokh Dehdashti) · dehdashtif@wustl.edu · 314-362-2809
    Contact: Principal Investigator (Farrokh Dehdashti)

  • Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

    Contact: Study coordinator (Hannah Linden) · hmlinden@uw.edu · 206-606-2053
    Contact: Principal Investigator (Hannah Linden)
Study leads

  • Hannah Linden

    Principal Investigator

    Fred Hutch/University of Washington Cancer Consortium

View source on ClinicalTrials.gov(opens in a new tab)